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Abstract: Despite therapeutic advances, colorectal cancer (CRC) is still one of the deadliest cancers,
partly due to local recurrence and metastatic disease. Tumour cells that spread by gaining access to
peripheral blood are called circulating tumour cells (CTCs). These may be present before there are
any clinical signs, but can be detected within blood samples. CTCs from patients with CRC may be
isolated in a laboratory for characterization and multiple analyses. In this review, we focus on the
prognostic potential of CTCs detection, by evaluating the reported progress and applications of such
analyses. Our search found 77 relevant studies that reported CTC detection in CRC. Both cell count
and features were reported as promising prognosis biomarkers. Since CTCs are rare and can lose their
differentiation, new tools are being developed to improve detection. CTCs may have potential as
prognostic biomarkers for CRC in terms of survival prediction, anticipating chemotherapy resistance,
and surgical planning. CTCs are not yet used in clinical practice, and further investigations are
required in order to better frame their practical value.
Keywords: circulating tumour cells; colorectal cancer; prognosis biomarker
1. Introduction
Colorectal cancer (CRC) is the third most common cause of cancer-related death
worldwide [1]. This high mortality may be explained by the relatively high incidence and
high rates of local regional and metastatic disease in CRC. The incidence is increasing in the
context of organised screening programmes and an ageing population. The preponderance
of advanced and metastatic disease is still a reality despite research advances in treatment.
Quality of life is a vital aspect of our care for patients with CRC, and individualised
treatments may help to limit side effects. Since prognostic biomarkers may allow for more
tailored treatments for our patients, circulating tumour cells (CTCs) have potential to be
helpful in this context.
The aim of this systematic review is to examine how CTCs in patients with CRC can be
used as prognostic biomarkers. We will summarise the progress reported in the literature
so far, and will discuss future research.
2. Circulating Tumour Cells (CTCs): Isolation Enrichment and Detection
CTCs are epithelial cancer cells from the primary tumour or metastases that gained
access to the circulatory system, and are detectable in sampled peripheral blood. They
are believed to be directly involved in the biology of the metastatic process [2]. From this
perspective, CTCs may then be defined as surrogate tumour material.
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Different techniques have been developed to isolate CTCs from the bloodstream,
based on biophysical methods (deformability, size, density, and surface charge), and/or
immunoaffinity status.
CellSearch is the only FDA-approved (Food Drug Administration) technology for CTC
isolation. It identifies Epithelial Cell Adhesion Molecule (EpCAM) expressing cells thanks to
antibody-labelled magnetic nanoparticles and the use of fluorescent microscopy to detect cy-
tokeratin()+ CK(+), DAPI(+), and CD45(−) cells [EpCAM(+)/CK(+)/CD45(−)/DAPI(+)] [3].
Once CTCs are isolated, they are available for multiple analyses such as genetic,
epigenetic, transcriptomic, proteomic, and identification of surface cell markers or living
cell properties. All these analyses have the potential to be used in the clinical setting for
either diagnosis, prognosis, prediction of recurrences, or to adapt therapeutics for different
types of solid cancers [4].
3. Review Methodology
We searched for published studies that reported the use of CTCs as a prognostic marker
for CRC patients. Our search was performed with PubMed from 1975 to 1 February 2021.
As search terms, we used “colorectal cancer (CRC)”, “circulating tumour cells (CTC)”, and
“prognosis biomarker”. All articles in English or French reporting information about CTCs,
CRC and prognosis were included in our initial search. We excluded all articles where the
study population was not patients with CRC. Case reports were excluded. Any articles
about CTCs that did not integrate prognostic factors were also excluded.
Articles were eligible for inclusion if they reported either quantitative data (pres-
ence/absence or number of CTCs) or qualitative data (specific CTC elements).
For the definition of “prognosis”, we included articles that discussed overall survival
regardless of the treatment, and those that discussed the sensitivity or resistance to a
specific treatment. We were also interested in discussions regarding treatment modulation,
such as adding or cancelling treatment, drug intensification or de-escalation, possibility of
targeted therapy, alternative treatment including early change or interruption of active care
(Figure 1). These were of interest because they facilitate precision medicine that enables us
to give the best care with the least side effect as possible.
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Figure 1. Colorectal cancer (CRC) circulating tumour cells (CTCs), from blood sample to clinical application.
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4. Results
We found 399 articles in our initial search. After excluding reports (Table 1) not
meeting the selection criteria (Table 1), there were 65 relevant studies (Figure 2). We
classified studies according to type of marker used (quantitative, qualitative or both),
techniques (Table 2), and their CTC detection time points (Figure 3). They are summarised
in Tables 3 and 4 and ??.
Table 1. Exclusion criteria.
Exclusion Criteria Number ofArticles
Other elements than CTCs: in liquid biopsy, non-circulating, microenvironment 163
Not CRC 22
Review or case report 74
CTCs research without prognostic angle 65
Other (languages, . . . ) 20
TOTAL 322
4.1. Types of Markers
The majority of articles use CTCs as a quantitative prognostic biomarker (Table 2).
This is likely to be due to the only FDA-approved method (CellSearch) being a CTC count
method. CellSearch, an EpCAM based technique, was used in 14 of the 77 included studies.
EpCAM is part of the cell adhesion molecule (CAM) family. It was first identified in
colon cancer in 1979 [70]. Epithelial Cell Adhesion Molecule (EpCAM) is expressed by
normal epithelial cells and is highly expressed in a majority (70%) of primary tumour.
Concerning colon adenocarcinomas, EpCAM is overexpressed in 81% [71] and it is
known to promote tumour expansion. EpCAM is involved in numerous independent
pathways [72]. It plays a part in the activation of the Wnt signalling pathway that is known
for its role in carcinogenesis. On one hand, EpCAM activates this pathway through its
interaction and stabilization of Lrp6. On the other hand, it downregulates the expression
of some this pathway inhibitors (fgf3). EpCAM is also known to promote oncogenesis
through its interaction with β -catenin, by activating cell proliferation via proto-oncogenes,
such as c-Myc or Cyclin A [73].
Thus, EpCAM is often use to characterise CTCs. However, during metastatic spread,
epithelial–mesenchymal transition (EMT) occurs and tumour cells lose their epithelial
marker, one of them being EpCAM. This cancer expansion modality highlights a clear limit
of anti-EpCAM based detection system [74].
In addition to this loss of specific markers, CTCs are also difficult to separate because
of their low concentration in the blood. To tackle these difficulties, newer strategies have
been proposed, such as the using blood samples close to the tumour, such as mesenteric
and portal vein blood samples, and detection methods such as specific gene reverse
transcriptase quantitative polymerase chain reaction (RT-qPCR). This quantitative RNA-
based method for CTC detection is more sensitive but has limitations. Target genes need
to be carefully selected as they can be weakly expressed in normal blood cells leading to
false-positives. Moreover if chosen target genes are expressed differently from one CTC to
another, this may lead to an inaccurate tumour cell count [75].
After total mononuclear cell RNA extraction, RT-PCR is conducted on mRNA that
are supposed to be specific to CTCs. More and more genes are being explored, focusing
on different CTCs characteristics, such as epithelial (CEA, CK20, and CK19) and stem
cells–like potential.
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4.2. Prognostic Thresholds
For studi s that utilised the CellSearch system, there were threshold changes according
to CRC stage. For metastatic CRC, CTC count above or equal to 3 CTC per 7.5 mL of blood
was used by Matsusaka et al., 2011 [5], Aggarwal et al., 2013 [7], and Sastre et al., 2013 [9] as
a positive marker to determine “high CTC” patients. These studies all reported a significant
correlation between baseline “high CTC” status and reduced survival. Camera et al.,
2020 [17], similarly reported a prognostic difference in the presence of disease refractory to
standard treatment or unresectable CRC. Coumans et al., 2012 [6], reported that survival
for patients with metastatic CRC patients with CTCs is reduced by 6.6 months for each
10-fold CTC increase.
Krebs et al., 2015 [11] and Aranda et al., 2020 [16] showed benefits of escalating therapy
from a three-drug regimen to a four-drug chemotherapy regimen for patients above their
CTC prognostic threshold.
For patients undergoing surgery, CTC count above or equal to 1 CTC per 7.5 mL
of blood was used by Bork et al., 2015 [10] and van Dalum et al., 2015 [13] to determine
survival. These finding suggest a reduced surgical utility for patients above the prognos-
tic threshold.
4.3. Techniques
There were multiple quantitative techniques other than CellSearch used in the in-
cluded studies. The epithelial markers CK20 and CEA were the most commonly used
among included studies. Taniguchi et al., 2000 [76] used CEA whereas Katsumata et al.,
2006 [24], and Hinz et al., 2017 [44], used CK2O, and reported a significant association
between CTC at time of surgery and survival. Allen-Mersh et al., 2007 [25] and Ito et al.,
2002 [21] used either one or both of these markers to investigate the correlation between
CTC detection after surgery and survival. For r ctal cancer patients, CK20 was chosen by
Hinz et al., 2015 [39], to pred ct non-response among rectal cancer undergoing neo-adjuvant
chemoradiation.
Other newer techniques are being developed such as combined markers detection [31]
or new molecule presence, like survivin [29].
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Table 3. Summary of quantitative included studies, separated into categories according to technique.









CTC count at baseline (B1), and at 2
(B3), and 8–12 weeks (B4) after
initiation of oxaliplatin-based
chemotherapy (folfox4 with or
without bevacizumab).
64 No M + CRC
Patients with ≥ 3 CTC at B1, at B3, and at
B4 had a shorter median PFS and median





CTC count before beginning (B1) of a
new line of therapy and at first
follow-up (B3).
428 Yes M + CRC
For each 10-fold CTC raise, survival of






CTC count at baseline (B1) and at 1–20
weeks (B3 et B4) after initiation of new
therapy.
217 No
M + CRC with a
baseline CEA value
≥ 25 ng/mL,
Patients with CTCs < 3 at B1 had longer
survival than those with high CTCs. In a





CellSearch Prospective CTC count during chemotherapy (B2). 14 No Stage III and IVM + CRC
They analysed the relationship between
CTC count and therapeutic outcome. A






CTC number at baseline (B1) and after
cycle 3 of chemotherapy and
bevacizumab (B3) and after disease
progression (B5).
158 No
M + CCR with
determined KRAS
status
Patients with < 3 CTC per 7.5 mL blood at
B1 and KRAS wild type tumours had a
significant better median PFS and OS than
patients with ≥ 3 CTCs and KRAS mutated





CellSearch Prospective CTC count preoperatively (A1) and onpostoperative days 3 and 7 (A3, A4). 287 No
CRC patients in 2
groups: complete
patient group and the
non-metastatic
cohort
(Stage I, II, and III).
Patients with ≥1 CTC per 7.5 mL had a
significantly worse OS in the non-metastatic
group, as well as in the complete cohort.
This strong prognostic factor for both
groups was confirm by multivariate
analysis.
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Baseline CTCs (B1) count allowing
stratifying patients into low (<3) and
high (≥3) CTC groups.
Patients undergoing a 4-drug regimen
called eSCOUT (irinotecan,









Compared with CRC undergoing CAIRO2
trial (3drug regimen).
For patients with CTC < 3, no differences
were found between the median OS in the
eSCOUT trial and in the CAIRO2 trial. For
patients with CTC > 3, median OS was






CTC count after primary tumour
resection (A3) and before the start of
adjuvant therapy (A4).






CTC count before surgery (A1) and at




(stage I, II and III)
M + CRC scheduled
for surgery
Patients with CTC at A1 had a significant
decrease in RFS, and CCRS. When using a
multivariate analysis, a significant
correlation was found between A1 CTC
presence and RFS. CTC detection during






CTC count in peripheral (PV) and
hepatic vein (HV) at the time of the
first liver operation (A2).
63 No




Patients with HV CTCs > 3 had a
significantly shorter DFS and OS. No
significant correlation was found between




CellSearch Prospective CTC count before therapy and afterone course of preoperative FOLFOX. 36 patients No




CTC detection rate at baseline was low to





CTC count at baseline (B1) before
receiving either FOLFOXIRI +
bevacizumab or FOLFOX +
bevacizumab every two weeks.
349 No
M + CRC previously
untreated,
unresectable with ≥
3 CTC/7.5 mL blood
at baseline (B1)
For M+ patients with CTC≥3, median PFS
was significantly higher with FOLFOXIRI
bevacizumab than with
FOLFOX-bevacizumab, although with a
higher rate of serious toxicities.
Int. J. Mol. Sci. 2021, 22, 3437 8 of 29
Table 3. Cont.









CTC count at day 1 and day 15 (B1).
No patient received any cancer













RT-PCR Prospective CTC presence before surgery (A1). 95 No
CRC
(6 Stage I, 32 Stage II,
37 Stage III, 20 stage
IV)
For the whole cohort or for the 68 patients
undergoing curative surgery, no significant







CTC in total and peripheral blood
during surgery (A1). 121 Yes
• 20 Stage I,
• 48 stage II,
• 34 stage III




No significant correlation was found
between positive rate and level of CEA






Tumour cells presence in peritoneal
lavage, peripheral blood before and
after surgery (A1, A3). In mesenteric
blood, during surgery (A2).
39 No
• 7 Stage I,
• 14 stage II,




There was a significant correlation between
dichotomous (CK20, CEA), qPCR covariate
and DFS or OS.
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CTC presence immediately before
(A1) and after surgery (A3). 99 Yes
• 5 stage 0,
• 19 stage I,
• 27 stage II,




Patients with positive CEA mRNA in
post-operative blood had a significantly






RT-PCR Prospective CTC presence 24 h after surgery (A3). 66 No
• 14 stage I,
• 28 stage II,




No significant correlation was found







CTC presence during surgery (A2) in
portal and peripheral blood. 100 No
• 20 stage I,
• 47 stage II,




Patients with CEA mRNA-positive portal
blood had a lower 4-year recurrence rate
than patients with CEA mRNA-negative
portal blood. There was no significative
correlation between DFS and CEA mRNA
positivity.
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RT-PCR NIF CTC presence during surgery (A2). 57 Yes
• Dukes’ stage A,
7 cases
• Stage B, 26 cases
• Stage C, 14
cases





CK20(+) patients had a significant lower







CTC presence 24h before surgery (A1),
and 24h (A3) and 1 week (A4) after
surgery.
199 Yes
• Dukes’ stage A,
30 cases
• Stage B, 69 cases
• Stage C, 47
cases






Patients with A3 positive blood sample for









NIF CTC presence at time of primarystaging (A1or B1). 37 No
• 11 stages I,
• 9 stages II,
• 9 stages III
• 8 stages IV
No significant correlation was found
between OS and CK20-positive cells
presence. Only a trend toward better
survival for CK20 (-) negative patients was
found.
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CTC presence between 7 and 10 days
after surgery (A3). 200 No
• 55 stages I,
• 86 stages II,
• 55 stages III
• all with curative
surgery
No correlation was found between
detection of CEA mRNA and
clinicopathological findings. Patients with
positive CEA mRNA showed significantly












T2 and 67% T3
There was a significant correlation between
RT-qPCR analysis of blood for CTCs and
OS.





NIF CTC presence at base line (A1 or B1). 86 Yes
• 21 cases stage I,
• 34 cases stage II,
• 22 cases stage
III
• 9 cases stage IV
There was a significant correlation between
survivin-expressing CTCs presence at
baseline (A1 or B1) and the degree of
tumour penetration, nodal status, disease







NIF CTC presence preoperatively (A1). 88 Yes
Astler–Coller
classification:
• 26 cases stage B,
• 27 cases stage C
• 31 cases stage D
• All with
curative surgery
6 groups of CRC patients were created:
group 0: no marker expression; group 1:
positive only for CEA; group 2: positive for
CEA and CK20; group 3: positive for all
three markers; group 4: patients of groups 1
and 2 and group 5: patients of groups 2 and
3.
There was a significant correlation between
OS and the different CRC patient groups.
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CTC presence at the pre surgery stage
and before chemotherapy begun (A1
or B1).
735 No
• Dukes’ stage A,
169 cases
• Stage B, 319
cases
• Stage C, 247
cases
Patients with positive CEA/CK/CD 133
had a significantly worse OS and DFS than






CTC presence after surgery and before
adjuvant systemic therapy (A3 or A4). 265 Yes
• 105 stage II
• 160 stage III
with curative
surgery
There was a significant correlation between
detection of CEACAM5m RNA-positive














• 4 cases stage II,
• 8 cases stage III
• 48 stages IV
Patients with CTC positivity (at least one of
the marker genes was positive) at B1 had a
significant shorter median PFS than
patients with no CTCs (all marker genes
were negative).




CTC presence on the day of initiation
of adjuvant chemotherapy (stage II
and III)(A4), or on the first day of
chemotherapy after diagnosis (M+)
(B1).
46 Yes
• 5 cases stage I,
• 8 cases stage II,
• 14 cases stage
III
• 19 cases stage
IV
Stage IV patients had a higher levels of
CEA mRNA, CK20 mRNA than patients at
stages I– III. There was a significant
correlation between peripheral blood CEA
mRNA levels and overall survival.
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Retrospective CTC presence immediately beforesurgery (A1). 50 Yes




There was a significant correlation between








NIF CTC presence from the mesentericvein during surgery (A2). 197 Yes
• 111 CRC with
Dukes’ stage B
• 86 cases with
stage C
• all with curative
surgery
There was a significant correlation between
CEA/CK/CD 133 expression and Dukes′
stage. Patients with Dukes′ stage B and C,
with CEA/CK/CD 133 positive in the
tumour drainage blood had a significantly




PLS3 RT-PCR NIF CTC presence before surgery (A1) 711 Yes
• Dukes’ Stage A,
85 cases
• Stage B, 309
cases
• Stage C, 234
cases
• Stage D, 83
cases
There was a significant correlation between
PLS3-positive CTC and prognosis in the
validation set. The association was
particularly strong in patients with Dukes B










CTC presence at baseline (B1) and at 4
(B3) and 16 weeks (B4) after treatment
onset.
50 Yes









They classified patients with at least four of
the six-gene panel markers below cut-offs,
as low-CTC. Moreover, those with three or
more markers above cut-offs in the
high-CTC group. Patients with high B1
CTC had a significant lower median PFS
and OS than patients with low CTC
markers.
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Non-responders had a significantly higher
CTC count than responders. There was a








NIF CTC presence. 150 Yes
• Stage I, 24 cases
• Stage II, 35
cases
• Stage III 55
cases
• Stage IV, 36
cases of
sporadic CRC
In patients with stage III disease, patients
with negative CD44v9 expression had a
significantly higher 5-year survival rate
than patients with positive expression. In
patients with stage IV unresectable cancer,
CD44v9-negative expression patients had a









CTC detection at baseline (B1), during
treatment (B2), at early (2–4weeks)








Samples were CTC-positive if at least one
of the 3 genes was above the threshold.
There was a significant correlation between
CTC status, CTC status changes during
treatment and tumour response. Patients
with early CTC(+) status had a significantly







Retrospective CTC presence at baseline (A1 or B1). 88 Yes M + CRC
Patients with high CTC-CK20 expression or
high CTC-survivin expression had a
significantly shortened median OS than
those with low expression of either marker.
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CTC presence on the day of the
surgery (A1) and 5 to 7 (A3) days after
surgery.
95 Yes
• Stage I, 22 cases
• Stage II, 30
cases
• Stage III, 30
cases
• Stage IV, 13
cases
Patients positive for CK20 postoperatively
(A1) had significant shorter PFS and OS





RT-PCR Prospective CTC presence at time of surgery (A1). 299 Yes
CRC with curative
surgery:
• Stage I, 87 cases
• Stage II, 94
cases
• stage III, 80
cases
• Stage IV, 38
cases
Patients with detectable CTC had a
significant lower 5-year OS rate than









Prospective CTC presence before (B1) and at 4 and16 weeks (B2) after treatment onset. 94 No




Patients where in the high/low CTCs
groups, when at least four markers were
above/below the individual cut-offs. There
was a significant correlation between all
CTC markers that presented an expression
above the cut-off (high CTC) and shorter
OS and PFS rates, both when analysed at
B1. Patients with increased expression of
CTC markers during treatment had a
shorter PFS and OS times than patients
presenting decreased expression.
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NIF CTC presence before treatment (B1). 78 Yes M + CRC
Patients with positive CTC Akt-2
expression had a significantly shorter
median PFS than those without. Patient
with positive CTC ALDH1 expression had a










NIF CTC presence at diagnosis (B1). 50 Yes
• 38 cases Stage
III
• 12 cases stage
IV relapsed
There was a significant correlation between












Prospective CTC detection at least 1 week aftersurgery (A3). 194 Yes
Stage II CRC with
curative surgery
There was a significant univariate
correlation between postoperative relapse
and the expression of all 4 mRNA markers.
For stage II patient, there was a significant
correlation between the expression of all 4
mRNA markers and poorer relapse-free
survival rates.








Retrospective CTC detection at 1 (A3) and 4 weeks(A4) after surgery. 141 No
Stage II and III CRC
with curative surgery
CTCs presence was positive if patients were
overexpressing all 4 molecular markers in
peripheral blood samples at A3 and A4.
There was a significant correlation between
persistent postoperative CTCs and early
postoperative (within one year) relapse,
poorer DFS and OS.
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CTC detection at 1 (B3) and 4 weeks
(B4) after completion of
chemotherapy.
90 No
Stage III CRC with
curative resection
followed by 12 cycles
of mFOLFOX
Patients had persistent presence of CTC if
they over expressed all 4 molecular
markers at both 1 (B3) and 4 weeks (B4)
after chemotherapy. There was a significant
correlation between persistent presence of













They detected 2 different populations of
CTCs: single cells or clusters. There was a
significant correlation between the presence










Prospective CTC detection during follow-upsurgery (A3). 298 No
• 82 cases Stage I,
• 102 cases Stage
II
• 114 cases Stage
III
There was a significant correlation between







CTC detection, 1 day before (A1), 1




• stage I and II
• 16 cases of stage
III–IV
No significant correlation was found
between survival and A1 CTC count.
At A4, CTC < 2 patients had a significantly
longer PFS than those with CTC ≥ 2. There
was a significant correlation between
decreased CTC number (compared with
preoperative CTC number) and longer PFS.
Int. J. Mol. Sci. 2021, 22, 3437 18 of 29
Table 3. Cont.









cytometry) Prospective CTC detection at baseline (B1). 55 No
M + CRC undergoing
palliative
chemotherapy
Patients with CTC number ≤ 30/mL had
significant lower median OS and PFS than
patients with CTC number > 30/mL. There
was a significant c on between median OS





Other (ISET) Prospective CTC detection before (A1) and aftersurgery (A3). 138 No
• 13 cases Stage I,
• 67 cases stage II,
• 58 cases stage
III
With a multivariate analysis, there was a
significant correlation between post-op, but
not pre-op CTCs+ and shorter 3-year RFS
rate.
Abbreviations: carcinoembryonic antigen (CEA), colon cancer related survival (CCRS), guanylyl cyclase C (GCC), cytokeratin 19 (CK19), cytokeratin 20 (CK20), colorectal liver metastasis (CRLM), confidence
interval (CI), disease-free survival (DFS), epidermal growth factor receptor (EGFR), hazard ratio (HR), isolation by Size of Epithelial Tumour Cells (ISET), metastatic colorectal cancer (M + CRC), non-metastatic
colorectal cancer (M − CRC), messenger ribonucleic acid (mRNA), no information found (NIF), overall survival (OS), progression-free survival (PFS), Plastin3 (PLS3), real-time quantitative polymerase chain
reaction (qPCR), recurrence-free survival (RFS), relative risk (RR), reverse transcriptase polymerase chain reaction (RT-PCR), real-time reverse transcriptase-polymerase chain reaction (RT-qPCR), subtraction
enrichment and immunostaining fluorescence in situ hybridization (SE-iFISH), time-to-therapeutic failure (TTF), vascular endothelial growth factor (VEGF).
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• Dukes’ stage A, 5 cases
• Stage B, 4 cases
• Stage C, 9 cases
• Stage D, 5 cases
There was no significant correlation
between positive rate of the mutated gene
in the blood and tumour stage. Patient with
p53 and/or K-RAS gene mutation-positive
findings had significantly shorter OS than
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PD-L1 (nPD-L1) expression and short
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In a multivariate analysis, patients with
high expression of CD133 + CD44 + CD54 +
cellular subpopulations had a worse
survival than those patients with low
expression. However, the survival of
patients who had resection for primary
tumour accompanied by surgical treatment
for metastasis was not correlated with the











CTCs detection at baseline
(A1 or B1) and on first
follow up (A3 or B3).
132 Yes
• 101 cases of stage I to III
• 31 cases M+
There was a significant correlation between
CK20 pCTC numbers and tumour node
metastasis stage and lymph node status.
Using the median CK20 pCTC numbers as
the cut-off points, there was a significant
correlation between recurrence, metastasis,







CTC detection at baseline
(B1). 63 No
KRAS wild type M + CRC
receiving cetuximab as third line
treatment
Patients with a high CTC count had a
significantly lower OS than patients with a
low number of CTCs. No significant
correlation was found between PFS and
high/low CTC status. There was no
significant correlation between clinical









Retrospective CTC detection beforechemotherapy (B1). 54 No
M + CRC starting a 5-FU based
chemotherapy
No significant association was found
between CTC TYMS staining and DP. There
was a significant correlation between CTC
count above 2 CTCs/mL and TYMS
expression, correlating with worse
prognosis.
Int. J. Mol. Sci. 2021, 22, 3437 21 of 29
Table 4. Cont.





CRC Stage and Mutational










CTC detection at baseline
(A1) and 6 weeks after
surgery (A4).
14 No
M + CRC with peritoneal
carcinomatosis and suitable for
treatment with CRS and HIPEC
There was a significant association between
the presence of CTCs and distant
dissemination and PFS. No significant
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ISH NIF NIF 1203 Yes
• 213 cases stage I,
• 438 cases stage II,
• 249 cases stage III
• 303 cases stage IV
Based on the expression of epithelial and
mesenchymal markers, three phenotypes
were defined: epithelial, biphenotypic, and
mesenchymal CTCs. There was a
significant correlation between CTC
numbers and clinical stage, lymph node
metastasis and distant metastasis.
Biphenotypic and mesenchymal, but not









Prospective CTC detection on 2peripheral blood sample. 63 Yes
M − CRC:
• 33 cases stages I and II,
• 30 cases stage III
In multivariate analysis, there was a
significant correlation between positive
CTCs for mRNA markers expression and





















There was a significant correlation between
CTC counts decreased between S1 and S2 in
patients and pCR or partial response.
Patients exhibiting pCR had negative TYMS
and RAD23B CTCs. There was an
association between, RAD23B expression
and non-responder status at S1 and S2.
Abbreviations: cytoreductive surgery (CRS), disease-free survival (DFS), disease progression (DP), hyperthermic intraperitoneal chemotherapy (HIPEC), in situ hybridization (ISH), non-metastatic colorectal
cancer (M − CRC), no information found (NIF), overall survival (OS), pathologic complete response (pCR), thymidylate synthase (TYMS).
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4.4. Qualitative Data from CTCs
There was some overlap in the reporting of quantitative and qualitative markers.
When CTC are detected without being destroyed, many complementary qualitative analy-
ses are available. Study investigators have focused on markers of the aggressiveness of
disease, expressed as either proteins (surface cell marker) or genes.
New marker development is focusing on discovering specific CTC subpopulations
that may have particular effects on prognosis. Zhao et al., 2017 [67] combined CTC
count and EMT state profile to predict disease aggressiveness. Tseng et al., 2015 [58]
correlated the presence of CD133+ CD44+ CD54+ CTC subpopulation with lower survival
in metastatic patients that did not undergo metastasis resection. Abdallah et al., 2016 [59]
used MRP1 positive CTC as a prognosis marker in patient that were going to initiate a new
chemotherapy agent.
Since markers are not always easy to determine [64], some clinicians try to associate
their detection with other techniques. One of them is to collect blood closer from the
tumour. Tseng et al., 2015 [58], used CTC analysis from mesenteric venous blood collected
while the patient was on the operating table.
5. Discussion
5.1. Main Findings
The main finding from our search of the literature regarding the prognostic utility of
CTCs for patients with CRC is that there are multiple quantitative and qualitative tests that
have been used, with some success, in predicting overall survival and success of treatment,
such as surgery and chemotherapy.
The presence of CTCs is a key risk factor for disease progression and severity. In breast
cancer, they are considered as efficient prognostic biomarkers and included in the 7th AJCC
Cancer Staging Manual (new category M0(i) introduced, and defined “by the presence of
circulating or disseminated tumour cells not exceeding 0.2 mm detectable in bone marrow,
circulating blood or other non-regional tissues of non-metastatic patients”. For patients
with CRC, this type of staging is not yet undertaken. Indeed, there is ongoing debate
regarding the utility of CTC detection due to the variations in techniques and conflicting
results [77,78]. Our review confirmed that there are a range of heterogeneous techniques
and results.
Most of our selected studies integrate metastatic patients (46/77). Additional prospec-
tive studies that investigate early CRC are needed in order to determine whether CTCs
have any prognostic utility in this context. Rectal cancer was the subject for only 3 of the
77 included studies, and requires further evaluation in prognostic studies.
Isolation and examination of CTCs allows different analyses focusing on a variety
of cell elements. The studies included in our review show that whatever quantitative or
qualitative techniques (or both) are used, CTCs have potential as biomarkers to predict
differences in outcomes such as survival and disease prognosis. To improve CTCs detection,
new biomarkers are being studied and selected in order to help distinguish CTCs from
other cells such as hematopoietic cells.
5.2. Detecting Circulating Tumour Cells
Since CTCs are epithelial cells that are found in the circulation, one option to detect
their presence would be to use epithelial markers, such as CEA and cytokeratins. CEA is
part of the immunoglobulin superfamily and is the product of the CEACAM5 gene [79],
and is involved in cellular adhesion. It is commonly found on the surface of small and large
bowels, rectum, pancreas, lung, and kidney cells. Being at a low rate for healthy people,
it is already being used in routine clinical practice as a biomarker for CRC. However, its
specificity is not the best as it can be increased in heavy smokers, inflammatory bowel
disease, chronic obstructive pulmonary disease, pancreatitis or other adenocarcinomas
than colorectal (such as ovaries, lung, kidney). On the RNA side, CEA mRNA can be
detected in almost all epithelial cells, including CTCs, and is not found in non-epithelial
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cells [80]. Cytokeratins are part of the intermediate filaments of epithelial cells cytoskeleton.
They are expressed in a tissue-specific manner. CK20 expression is limited to the gastric
and intestinal epithelium, urothelium, and Merkel cells, and from malignancies that orig-
inate from these sites [30,81,82]. CK20 is not expressed in hematopoietic cells [83]. The
main limitation of these biomarkers is that cancer cells undergo epithelial–mesenchymal
transition (EMT) in the circulation, which can cause down regulation of epithelial markers.
Therefore, these markers will only partially detect CTCs.
Yokobori et al., 2013 [37] chose to detect CTCs by using a marker that is not lost
during the EMT process: plastin3 (PLS3). It codes for a ubiquitous protein that inhibits
depolymerization of actin fibres. PLS3 is actually an EMT inducer and is therefore over-
expressed by CTCs [84]. While working on EMT, Armstrong et al., 2011 [85] found that
CTCs expressed both epithelial, and stem cell markers. Some of the included studies utilised
stemness markers such as survivin, CD44 variants 6 and 9, and CD133. A good strategy
seems to combine both categories of markers (epithelial and stemness) [42]. Survivin is an
inhibitor of apoptosis and is highly conserved in CTCs cells. By limiting this programmed
cell death, tumour cells develop aggressiveness [86]. Survivin is found in many cancer
tissues, including CRC [29] and is not expressed in normal ones [87].
CD44 is a gene involved in adhesion cells and growth and invasion in tumour cells.
CD44 is expressed by metastasis initiating cells [88] also known as cancer stem cells in
CRC, but its exact function in these particular cells is still unknown, especially the exon
that plays the central role [89]. CD133 (also known as prominin-1), is a transmembrane
protein, initially described on the surface of hematopoietic stem cells; it is now known
as a stemness marker for normal and cancer cells. It is not specific for CRC [90], but is
considered as a key marker of tumoural stem cells in CRC [31]. Metastatic colon tissues are
formed of CD133 (+) and (−) cells that can both initiate tumour cells. Since CD133 is also
known to be expressed by endothelial cells, its expression by RT-PCR might be caused by
bone marrow-derived circulating endothelial cells [35].
Other biomarkers with a key role in cancer biology have also been investigated in order
to identify subpopulations of CTCs with a higher potential for aggressiveness [35]. Epithe-
lial growth factor receptor (EGFR) is expressed in different cell types except hematopoietic
cells and is commonly used as a therapeutic target in CRC. As more and more anti-EGFR
resistance is identified, it may become important to detect CTC modification in terms of its
expression of EGFR during anti-EGFR treatment [41]. Similarly, as TYMS polymorphisms
seem predict response to 5FU–based chemotherapy [91], which is the main chemotherapy
used as a neoadjuvant setting before rectal surgery, and also the ultraviolet excision repair
protein, RAD23 homolog B (RAD23B), which potentially be “induced by the genetic dam-
age introduced by radiotherapy” [92] before rectal surgery, both monitoring of thymidylate
synthase (TYMS) and excision repair protein, RAD23 homolog B (RAD23B), can be used to
predict resistance to chemotherapy/radiotherapy used in rectal cancers [69].
5.3. The Future
Our updated review confirms the potential of CTC biomarker detection as a prognostic
tool, in keeping with the findings of a previous meta-analysis [93]. Molecular characteri-
zation at both cellular and genomic levels may be of utility in the prognosis for patients
with CRC, whatever the initial stage (metastatic or not). Furthermore, where CTCs remain
present despite chemotherapy treatment, this may be used to indicate failure of therapy
and predict survival. CTCs remain of great interest to clinicians who look after patients
with CRC due to their potential for utilization in clinical practice. They might give a
“snapshot” of the disease within time and space, and enable the individualised therapy
for patients. This may be possible by identifying patients at risk, facilitate more accurate
cancer surveillance and potentially the adaptation of treatments. One focus for the future
application of such a test would be the search for the most sensitive and specific (and
cost-effective) method for use in routine daily clinical practice.
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There were a number of articles excluded because they focused on other liquid
biopsy techniques. However, they demonstrate the breadth of interest in the search
for applicable circulating prognostic biomarkers for CRC. Some include the “OMICS”
(circulating tumoural DNA, miRNA, circulating protein), the microenvironment (tumour-
derived exosomes, circulating immune cells with tumour associated macrophage) and neo-
vascularisation (circulating endothelial cell, VEGF [Vascular Endothelial Growth Factor],
EPC [endothelial progenitor cells], CEC [Circulating endothelial cells]) [94]. Interestingly,
some of these other biomarkers made CTCs less prevalent. For example, DNA mutation
analysis is now often assessed on circulating tumour DNA rather than on CTC [95].
Several interesting avenues require further evaluation concerning the detection and
analysis of CTCs. There may be some role in early diagnosis through screening [96]. CTCs
may also be helpful in identifying cancer primary site [97] in cases where there is diagnostic
uncertainty. Further investigations regarding tumour biology and the metastatic process
are in development, focusing on tumour microenvironment, the epithelial to mesenchymal
transition, circulating cancer cell stemness, and others [98,99]. Furthermore, when CTC are
isolated without being destroyed, CTC-derived xenografts could lead to patient specific
drug screening [100–102].
6. Conclusions
We identified 77 studies that reported data regarding the prognostic utility of CTCs for
patients with CRC. CTCs seem to have a high potential for use as a prognostic biomarker
in CRC in both quantitative and qualitative terms. Ongoing investigations are required to
evaluate the role of CTC analysis in routine clinical practice.
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43. Kust, D.; Šamija, I.; Kirac, I.; Radić, J.; Kovačević, D.; Kusić, Z. Cytokeratin 20 positive cells in blood of colorectal cancer patients
as an unfavorable prognostic marker. Acta Clin. Belg. 2016, 71, 235–243. [CrossRef]
44. Hinz, S.; Hendricks, A.; Wittig, A.; Schafmayer, C.; Tepel, J.; Kalthoff, H.; Becker, T.; Röder, C. Detection of circulating tumor cells
with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients—A prospective study. BMC Cancer
2017, 17, 53. [CrossRef] [PubMed]
45. Insua, Y.V.; de la Cámara, J.; Vázquez, E.B.; Fernández, A.; Rivera, F.V.; Silva, M.J.V.V.; Barbazán, J.; Muinelo-Romay, L.; Folgar,
S.C.; Abalo, A.; et al. Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection
by a Multigene Expression Panel: A Multicentric Prospective Validation Study. Int. J. Mol. Sci. 2017, 18, 1265. [CrossRef]
[PubMed]
46. Ning, Y.; Zhang, W.; Hanna, D.L.; Yang, D.; Okazaki, S.; Berger, M.D.; Miyamoto, Y.; Suenaga, M.; Schirripa, M.; El-Khoueiry,
A.; et al. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.
Pharmacogenomics J. 2018, 18, 29–34. [CrossRef] [PubMed]
47. Shou, X.; Li, Y.; Hu, W.; Ye, T.; Wang, G.; Xu, F.; Sui, M.; Xu, Y. Six-gene Assay as a new biomarker in the blood of patients with
colorectal cancer: Establishment and clinical validation. Mol. Oncol. 2019, 13, 781–791. [CrossRef]
48. Uen, Y.-H.; Lin, S.-R.; Wu, D.-C.; Su, Y.-C.; Wu, J.-Y.; Cheng, T.-L.; Chi, C.-W.; Wang, J.-Y. Prognostic significance of multiple
molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann. Surg. 2007, 246, 1040–1046.
[CrossRef]
49. Lu, C.-Y.; Uen, Y.-H.; Tsai, H.-L.; Chuang, S.-C.; Hou, M.-F.; Wu, D.-C.; Juo, S.-H.H.; Lin, S.-R.; Wang, J.-Y. Molecular detection of
persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: Prognostic
significance of detection for early relapse. Br. J. Cancer 2011, 104, 1178–1184. [CrossRef]
50. Lu, C.-Y.; Tsai, H.-L.; Uen, Y.-H.; Hu, H.-M.; Chen, C.-W.; Cheng, T.-L.; Lin, S.-R.; Wang, J.-Y. Circulating tumor cells as a surrogate
marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br. J. Cancer 2013,
108, 791–797. [CrossRef] [PubMed]
51. Divella, R.; Daniele, A.; Abbate, I.; Bellizzi, A.; Savino, E.; Simone, G.; Giannone, G.; Giuliani, F.; Fazio, V.; Gadaleta-Caldarola,
G.; et al. The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in
metastatic colorectal cancer. Cancer Causes Control CCC 2014, 25, 1531–1541. [CrossRef] [PubMed]
52. Chang, Y.-T.; Huang, M.-Y.; Yeh, Y.-S.; Huang, C.-W.; Tsai, H.-L.; Cheng, T.-L.; Wang, J.-Y. A Prospective Study of Comparing
Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III
Colorectal Cancer. PLoS ONE 2016, 11, e0163264. [CrossRef] [PubMed]
53. Wu, W.; Zhang, Z.; Gao, X.H.; Shen, Z.; Jing, Y.; Lu, H.; Li, H.; Yang, X.; Cui, X.; Li, Y.; et al. Clinical significance of detecting
circulating tumor cells in colorectal cancer using subtraction enrichment and immunostaining-fluorescence in situ hybridization
(SE-iFISH). Oncotarget 2017, 8, 21639–21649. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 3437 27 of 29
54. Chou, W.-C.; Wu, M.-H.; Chang, P.-H.; Hsu, H.-C.; Chang, G.-J.; Huang, W.-K.; Wu, C.-E.; Hsieh, J.C.-H. A Prognostic Model
Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal
Cancer. Int. J. Biol. Sci. 2018, 14, 137–146. [CrossRef]
55. Yang, C.; Shi, D.; Wang, S.; Wei, C.; Zhang, C.; Xiong, B. Prognostic value of pre- and post-operative circulating tumor cells
detection in colorectal cancer patients treated with curative resection: A prospective cohort study based on ISET device. Cancer
Manag. Res. 2018, 10, 4135–4144. [CrossRef]
56. Iinuma, H.; Okinaga, K.; Adachi, M.; Suda, K.; Sekine, T.; Sakagawa, K.; Baba, Y.; Tamura, J.; Kumagai, H.; Ida, A. Detection of
tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and
K-ras genes in patients with colorectal cancer. Int. J. Cancer 2000, 89, 337–344. [CrossRef]
57. Gazzaniga, P.; Gradilone, A.; Petracca, A.; Nicolazzo, C.; Raimondi, C.; Iacovelli, R.; Naso, G.; Cortesi, E. Molecular markers in
circulating tumour cells from metastatic colorectal cancer patients. J. Cell. Mol. Med. 2010, 14, 2073–2077. [CrossRef] [PubMed]
58. Tseng, J.-Y.; Yang, C.-Y.; Yang, S.-H.; Lin, J.-K.; Lin, C.-H.; Jiang, J.-K. Circulating CD133(+)/ESA(+) cells in colorectal cancer
patients. J. Surg. Res. 2015, 199, 362–370. [CrossRef] [PubMed]
59. Abdallah, E.A.; Fanelli, M.F.; Souza E Silva, V.; Machado Netto, M.C.; Gasparini, J.L., Jr.; Araújo, D.V.; Ocea, L.M.M.; Buim,
M.E.C.; Tariki, M.S.; da Silva Alves, V.; et al. MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in
metastatic colorectal cancer. Int. J. Cancer 2016, 139, 890–898. [CrossRef]
60. Barbazan, J.; Dunkel, Y.; Li, H.; Nitsche, U.; Janssen, K.-P.; Messer, K.; Ghosh, P. Prognostic Impact of Modulators of G proteins in
Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer. Sci. Rep. 2016, 6, 22112. [CrossRef] [PubMed]
61. Satelli, A.; Batth, I.S.; Brownlee, Z.; Rojas, C.; Meng, Q.H.; Kopetz, S.; Li, S. Potential role of nuclear PD-L1 expression in
cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci. Rep. 2016, 6, 28910. [CrossRef]
[PubMed]
62. Fang, C.; Fan, C.; Wang, C.; Huang, Q.; Meng, W.; Yu, Y.; Yang, L.; Hu, J.; Li, Y.; Mo, X.; et al. Prognostic value of CD133+ CD54+
CD44+ circulating tumor cells in colorectal cancer with liver metastasis. Cancer Med. 2017, 6, 2850–2857. [CrossRef]
63. Wong, S.C.C.; Chan, C.M.L.; Ma, B.B.Y.; Hui, E.P.; Ng, S.S.M.; Lai, P.B.S.; Cheung, M.T.; Lo, E.S.F.; Chan, A.K.C.; Lam, M.Y.Y.; et al.
Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in
colorectal cancer patients. Clin. Cancer Res. 2009, 15, 1005–1012. [CrossRef]
64. Kuboki, Y.; Matsusaka, S.; Minowa, S.; Shibata, H.; Suenaga, M.; Shinozaki, E.; Mizunuma, N.; Ueno, M.; Yamaguchi, T.; Hatake,
K. Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab
efficacy in advanced colorectal cancer. Anticancer Res. 2013, 33, 3905–3910. [PubMed]
65. Abdallah, E.A.; Fanelli, M.F.; Buim, M.E.C.; Machado Netto, M.C.; Gasparini, J.L., Jr.; Souza E Silva, V.; Dettino, A.L.A.; Mingues,
N.B.; Romero, J.V.; Ocea, L.M.M.; et al. Thymidylate synthase expression in circulating tumor cells: A new tool to predict
5-fluorouracil resistance in metastatic colorectal cancer patients. Int. J. Cancer 2015, 137, 1397–1405. [CrossRef]
66. Melero, J.T.; Ortega, F.G.; Gonzalez, A.M.; Carmona-Saez, P.; Garcia Puche, J.L.; Sugarbaker, P.H.; Delgado, M.; Lorente, J.A.;
Serrano, M.J. Prognostic factor analysis of circulating tumor cells in peripheral blood of patients with peritoneal carcinomatosis
of colon cancer origin treated with cytoreductive surgery plus an intraoperative hyperthermic intraperitoneal chemotherapy
procedure (CRS + HIPEC). Surgery 2016, 159, 728–735. [CrossRef] [PubMed]
67. Zhao, R.; Cai, Z.; Li, S.; Cheng, Y.; Gao, H.; Liu, F.; Wu, S.; Liu, S.; Dong, Y.; Zheng, L.; et al. Expression and clinical relevance of
epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer. Oncotarget 2017, 8, 9293–9302. [CrossRef]
68. Bahnassy, A.A.; Salem, S.E.; Mohanad, M.; Abulezz, N.Z.; Abdellateif, M.S.; Hussein, M.; Zekri, C.A.N.; Zekri, A.-R.N.;
Allahloubi, N.M.A. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients:
A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and
Cytomorphology). Exp. Mol. Pathol. 2019, 106, 90–101. [CrossRef] [PubMed]
69. Troncarelli Flores, B.C.; Souza E Silva, V.; Ali Abdallah, E.; Mello, C.A.L.; Gobo Silva, M.L.; Gomes Mendes, G.; Camila Braun, A.;
Aguiar, S., Jr.; Thomé Domingos Chinen, L. Molecular and Kinetic Analyses of Circulating Tumor Cells as Predictive Markers of
Treatment Response in Locally Advanced Rectal Cancer Patients. Cells 2019, 8, 641. [CrossRef] [PubMed]
70. Herlyn, M.; Steplewski, Z.; Herlyn, D.; Koprowski, H. Colorectal carcinoma-specific antigen: Detection by means of monoclonal
antibodies. Proc. Natl. Acad. Sci. USA 1979, 76, 1438–1442. [CrossRef]
71. Went, P.T.; Lugli, A.; Meier, S.; Bundi, M.; Mirlacher, M.; Sauter, G.; Dirnhofer, S. Frequent EpCam protein expression in human
carcinomas. Hum. Pathol. 2004, 35, 122–128. [CrossRef]
72. Huang, L.; Yang, Y.; Yang, F.; Liu, S.; Zhu, Z.; Lei, Z.; Guo, J. Functions of EpCAM in physiological processes and diseases
(Review). Int. J. Mol. Med. 2018, 42, 1771–1785. [CrossRef] [PubMed]
73. Maetzel, D.; Denzel, S.; Mack, B.; Canis, M.; Went, P.; Benk, M.; Kieu, C.; Papior, P.; Baeuerle, P.A.; Munz, M.; et al. Nuclear
signalling by tumour-associated antigen EpCAM. Nat. Cell Biol. 2009, 11, 162–171. [CrossRef] [PubMed]
74. Gorges, T.M.; Tinhofer, I.; Drosch, M.; Röse, L.; Zollner, T.M.; Krahn, T.; von Ahsen, O. Circulating tumour cells escape from
EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012, 12, 178. [CrossRef] [PubMed]
75. Andergassen, U.; Kölbl, A.C.; Mahner, S.; Jeschke, U. Real-time RT-PCR systems for CTC detection from blood samples of breast
cancer and gynaecological tumour patients (Review). Oncol. Rep. 2016, 35, 1905–1915. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 3437 28 of 29
76. Taniguchi, T.; Makino, M.; Suzuki, K.; Kaibara, N. Prognostic significance of reverse transcriptase-polymerase chain reaction
measurement of carcinoembryonic antigen mRNA levels in tumor drainage blood and peripheral blood of patients with colorectal
carcinoma. Cancer 2000, 89, 970–976. [CrossRef]
77. Yang, C.; Zou, K.; Zheng, L.; Xiong, B. Prognostic and clinicopathological significance of circulating tumor cells detected by
RT-PCR in non-metastatic colorectal cancer: A meta-analysis and systematic review. BMC Cancer 2017, 17, 725. [CrossRef]
78. Vojtechova, G.; Benesova, L.; Belsanova, B.; Minarikova, P.; Levy, M.; Lipska, L.; Suchanek, S.; Zavoral, M.; Minarik, M.
Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer
Patients Undergoing Surgery. Adv. Clin. Exp. Med. Off. Organ Wroclaw Med. Univ. 2016, 25, 1273–1279. [CrossRef]
79. Kuespert, K.; Pils, S.; Hauck, C.R. CEACAMs: Their role in physiology and pathophysiology. Curr. Opin. Cell Biol. 2006, 18,
565–571. [CrossRef]
80. Mori, M.; Mimori, K.; Ueo, H.; Karimine, N.; Barnard, G.F.; Sugimachi, K.; Akiyoshi, T. Molecular detection of circulating solid
carcinoma cells in the peripheral blood: The concept of early systemic disease. Int. J. Cancer 1996, 68, 739–743. [CrossRef]
81. Ribal, M.J.; Mengual, L.; Marín, M.; Algaba, F.; Ars, E.; Fernández, P.L.; Oliva, R.; Villavicencio, H.; Alcaraz, A. Molecular staging
of bladder cancer with RT-PCR assay for CK20 in peripheral blood, bone marrow and lymph nodes: Comparison with standard
histological staging. Anticancer Res. 2006, 26, 411–419. [PubMed]
82. Moll, R.; Löwe, A.; Laufer, J.; Franke, W.W. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by
monoclonal antibodies. Am. J. Pathol. 1992, 140, 427–447. [PubMed]
83. Burchill, S.A.; Bradbury, M.F.; Pittman, K.; Southgate, J.; Smith, B.; Selby, P. Detection of epithelial cancer cells in peripheral blood
by reverse transcriptase-polymerase chain reaction. Br. J. Cancer 1995, 71, 278–281. [CrossRef] [PubMed]
84. Sugimachi, K.; Yokobori, T.; Iinuma, H.; Ueda, M.; Ueo, H.; Shinden, Y.; Eguchi, H.; Sudo, T.; Suzuki, A.; Maehara, Y.; et al.
Aberrant expression of plastin-3 via copy number gain induces the epithelial-mesenchymal transition in circulating colorectal
cancer cells. Ann. Surg. Oncol. 2014, 21, 3680–3690. [CrossRef] [PubMed]
85. Armstrong, A.J.; Marengo, M.S.; Oltean, S.; Kemeny, G.; Bitting, R.L.; Turnbull, J.D.; Herold, C.I.; Marcom, P.K.; George, D.J.;
Garcia-Blanco, M.A. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and
mesenchymal markers. Mol. Cancer Res. MCR 2011, 9, 997–1007. [CrossRef]
86. Sarela, A.I.; Macadam, R.C.; Farmery, S.M.; Markham, A.F.; Guillou, P.J. Expression of the antiapoptosis gene, survivin, predicts
death from recurrent colorectal carcinoma. Gut 2000, 46, 645–650. [CrossRef]
87. Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997,
3, 917–921. [CrossRef]
88. Todaro, M.; Gaggianesi, M.; Catalano, V.; Benfante, A.; Iovino, F.; Biffoni, M.; Apuzzo, T.; Sperduti, I.; Volpe, S.; Cocorullo, G.; et al.
CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 2014, 14,
342–356. [CrossRef]
89. Kimura, Y.; Goi, T.; Nakazawa, T.; Hirono, Y.; Katayama, K.; Urano, T.; Yamaguchi, A. CD44variant exon 9 plays an important
role in colon cancer initiating cells. Oncotarget 2013, 4, 785–791. [CrossRef]
90. Shmelkov, S.V.; Butler, J.M.; Hooper, A.T.; Hormigo, A.; Kushner, J.; Milde, T.; St Clair, R.; Baljevic, M.; White, I.; Jin, D.K.; et al.
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J. Clin.
Investig. 2008, 118, 2111–2120. [CrossRef]
91. Tsuji, T.; Hidaka, S.; Sawai, T.; Nakagoe, T.; Yano, H.; Haseba, M.; Komatsu, H.; Shindou, H.; Fukuoka, H.; Yoshinaga, M.; et al.
Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to
5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2003, 9,
3700–3704.
92. Schauber, C.; Chen, L.; Tongaonkar, P.; Vega, I.; Lambertson, D.; Potts, W.; Madura, K. Rad23 links DNA repair to the ubiqui-
tin/proteasome pathway. Nature 1998, 391, 715–718. [CrossRef] [PubMed]
93. Tan, Y.; Wu, H. The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and
meta-analysis. Curr. Probl. Cancer 2018, 42, 95–106. [CrossRef]
94. Ramcharan, S.K.; Lip, G.Y.H.; Stonelake, P.S.; Blann, A.D. Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes’
and AJCC stage in colorectal cancer. Eur. J. Clin. Invest. 2013, 43, 801–808. [CrossRef]
95. Germano, G.; Mauri, G.; Siravegna, G.; Dive, C.; Pierce, J.; Di Nicolantonio, F.; D’Incalci, M.; Bardelli, A.; Siena, S.; Sartore-Bianchi,
A. Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Clin. Colorectal
Cancer 2018, 17, 80–83. [CrossRef]
96. Yeh, C.-S.; Wang, J.-Y.; Wu, C.-H.; Chong, I.-W.; Chung, F.-Y.; Wang, Y.-H.; Yu, Y.-P.; Lin, S.-R. Molecular detection of circulating
cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker
panel. Int. J. Oncol. 2006, 28, 411–420. [CrossRef] [PubMed]
97. Lu, S.-H.; Tsai, W.-S.; Chang, Y.-H.; Chou, T.-Y.; Pang, S.-T.; Lin, P.-H.; Tsai, C.-M.; Chang, Y.-C. Identifying cancer origin using
circulating tumor cells. Cancer Biol. Ther. 2016, 17, 430–438. [CrossRef]
98. Padín-Iruegas, M.-E.; Herranz-Carnero, M.; Aguin-Losada, S.; Brozos-Vazquez, E.; Anido-Herranz, U.; Antunez-Lopez, J.-R.;
Ruibal-Morell, A.; López-López, R. Prognostic value of changes in the expression of stem cell markers in the peripheral blood of
patients with colon cancer. Oncol. Rep. 2013, 29, 2467–2472. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 3437 29 of 29
99. Visioli, A.; Giani, F.; Trivieri, N.; Pracella, R.; Miccinilli, E.; Cariglia, M.G.; Palumbo, O.; Arleo, A.; Dezi, F.; Copetti, M.; et al.
Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies. EBioMedicine 2019,
44, 346–360. [CrossRef]
100. Cayrefourcq, L.; Mazard, T.; Joosse, S.; Solassol, J.; Ramos, J.; Assenat, E.; Schumacher, U.; Costes, V.; Maudelonde, T.; Pantel,
K.; et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015, 75, 892–901.
[CrossRef] [PubMed]
101. Malara, N.; Trunzo, V.; Foresta, U.; Amodio, N.; De Vitis, S.; Roveda, L.; Fava, M.; Coluccio, M.; Macrì, R.; Di Vito, A.; et al. Ex-vivo
characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for
personalized metastatic risk assessment. J. Transl. Med. 2016, 14, 133. [CrossRef] [PubMed]
102. Pei, H.; Li, L.; Wang, Y.; Sheng, R.; Wang, Y.; Xie, S.; Shui, L.; Si, H.; Tang, B. Single-Cell Phenotypic Profiling of CTCs in Whole
Blood Using an Integrated Microfluidic Device. Anal. Chem. 2019, 91, 11078–11084. [CrossRef] [PubMed]
